Re-inforcing the cell death army in the fight against breast cancer

被引:18
作者
Oudenaarden, Clara R. L. [1 ,2 ]
van de Ven, Robert A. H. [1 ,3 ]
Derksen, Patrick W. B. [1 ]
机构
[1] UMC Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Lund Univ, Dept Expt Oncol, Scheelevagen 2, S-22363 Lund, Sweden
[3] Harvard Med Sch, Dept Cell Biol, 250 Longwood Ave, Boston, MA 02115 USA
基金
欧盟地平线“2020”;
关键词
Breast cancer; Intrinsic apoptosis; Metastasis; MAMMARY-GLAND DEVELOPMENT; BCL-2 PROTEIN FAMILY; OBATOCLAX MESYLATE; E-CADHERIN; PROMOTES TUMORIGENESIS; REDUCED EXPRESSION; BH3-ONLY PROTEINS; BH3; DOMAIN; APOPTOSIS; BIM;
D O I
10.1242/jcs.212563
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metastatic breast cancer is responsible for most breast cancer-related deaths. Disseminated cancer cells have developed an intrinsic ability to resist anchorage-dependent apoptosis (anoikis). Anoikis is caused by the absence of cellular adhesion, a process that underpins lumen formation and maintenance during mammary gland development and homeostasis. In healthy cells, anoikis is mostly governed by B-cell lymphoma-2 (BCL2) protein family members. Metastatic cancer cells, however, have often developed autocrine BCL2-dependent resistance mechanisms to counteract anoikis. In this Review, we discuss how a pro-apoptotic subgroup of the BCL2 protein family, known as the BH3-only proteins, controls apoptosis and anoikis during mammary gland homeostasis and to what extent their inhibition confers tumor suppressive functions in metastatic breast cancer. Specifically, the role of the two pro-apoptotic BH3-only proteins BCL2-modifying factor (BMF) and BCL2-interacting mediator of cell death (BIM) will be discussed here. We assess current developments in treatment that focus on mimicking the function of the BH3-only proteins to induce apoptosis, and consider their applicability to restore normal apoptotic responses in anchorage-independent disseminating tumor cells.
引用
收藏
页数:11
相关论文
共 119 条
[1]   Nomenclature of dynein light chain-linked BH3-only protein Bim isoforms [J].
Adachi, M ;
Zhao, X ;
Imai, K .
CELL DEATH AND DIFFERENTIATION, 2005, 12 (02) :192-193
[2]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[3]   Bim-targeted cancer therapy: A link between drug action and underlying molecular changes [J].
Akiyama, Toru ;
Dass, Crispin R. ;
Choong, Peter F. M. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) :3173-3180
[4]  
[Anonymous], 2013, J CARCINOG MUTAGEN, DOI DOI 10.4172/2157-2518.S7-003
[5]   Evolution of Bcl-2 homology motifs: homology versus homoplasy [J].
Aouacheria, Abdel ;
de Laval, Valentine Rech ;
Combet, Christophe ;
Hardwick, J. Marie .
TRENDS IN CELL BIOLOGY, 2013, 23 (03) :103-111
[6]   Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database [J].
Autier, Philippe ;
Boniol, Mathieu ;
LaVecchia, Carlo ;
Vatten, Lars ;
Gavin, Anna ;
Hery, Clarisse ;
Heanue, Mary .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 :335
[7]   EXPRESSION OF THE BCL-2 GENE FAMILY IN NORMAL AND MALIGNANT BREAST-TISSUE - LOW BAX-ALPHA EXPRESSION IN TUMOR-CELLS CORRELATES WITH RESISTANCE TOWARDS APOPTOSIS [J].
BARGOU, RC ;
DANIEL, PT ;
MAPARA, MY ;
BOMMERT, K ;
WAGENER, C ;
KALLINICH, B ;
ROYER, HD ;
DORKEN, B .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (06) :854-859
[8]   BH3 Mimetics: Status of the Field and New Developments [J].
Billard, Christian .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) :1691-1700
[9]   The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 [J].
Blume-Jensen, P ;
Janknecht, R ;
Hunter, T .
CURRENT BIOLOGY, 1998, 8 (13) :779-782
[10]  
Bodis S, 1996, CANCER, V77, P1831